Save information for later
Sign Up

Learn About Gastrointestinal Stromal Tumor

What is the definition of Gastrointestinal Stromal Tumor?

A gastrointestinal stromal tumor (GIST) is a type of tumor that occurs in the gastrointestinal tract, most commonly in the stomach or small intestine. This type of tumor is thought to grow from specialized cells found in the gastrointestinal tract called interstitial cells of Cajal (ICCs) or precursors to these cells. Affected individuals can develop one or more tumors. GISTs are usually found in adults between ages 40 and 70; rarely, children and young adults develop this type of tumor.

What are the causes of Gastrointestinal Stromal Tumor?

Genetic changes in one of several genes are involved in the formation of GISTs. About 80 percent of cases are associated with a mutation in the KIT gene, and about 10 percent of cases are associated with a mutation in the PDGFRA gene. Mutations in the KIT and PDGFRA genes are associated with both familial and sporadic GISTs. Less than 10 percent of cases are SDH-deficient GISTs, which are associated with mutations or other changes in the SDHA, SDHB, SDHC, or SDHD gene. SDH-deficient GIST can be familial or sporadic. A small number of people with a GIST have mutations in other genes.

How prevalent is Gastrointestinal Stromal Tumor?

Approximately 5,000 new cases of GIST are diagnosed in the United States each year. SDH-deficient GIST accounts for about 5 to 7 percent of cases. However, GISTs may be more common than the estimate because small tumors may remain undiagnosed.

Is Gastrointestinal Stromal Tumor an inherited disorder?

Most cases of GIST are sporadic and are not inherited. These cases are associated with a somatic mutation, which is a genetic change that occurs only in the tumor cells and occurs during a person's lifetime.

Who are the top Gastrointestinal Stromal Tumor Local Doctors?
Mark A. Dickson
Elite in Gastrointestinal Stromal Tumor
Hematology Oncology | Hematology | Oncology
Elite in Gastrointestinal Stromal Tumor
Hematology Oncology | Hematology | Oncology

Memorial Solid Tumor Group

160 E 53rd St, 
New York, NY 
Languages Spoken:
English
Offers Telehealth

Mark Dickson is a Hematologist Oncology specialist and a Hematologist in New York, New York. Dr. Dickson is rated as an Elite provider by MediFind in the treatment of Gastrointestinal Stromal Tumor. His top areas of expertise are Adult Soft Tissue Sarcoma, Liposarcoma, Undifferentiated Pleomorphic Sarcoma, Gastrointestinal Stromal Tumor, and Endoscopy.

Elite in Gastrointestinal Stromal Tumor
Hematology Oncology | Hematology | Oncology
Elite in Gastrointestinal Stromal Tumor
Hematology Oncology | Hematology | Oncology

Memorial Solid Tumor Group

160 E 53rd St, 
New York, NY 
Languages Spoken:
English
Offers Telehealth

William Tap is a Hematologist Oncology specialist and a Hematologist in New York, New York. Dr. Tap is rated as an Elite provider by MediFind in the treatment of Gastrointestinal Stromal Tumor. His top areas of expertise are Adult Soft Tissue Sarcoma, Gastrointestinal Stromal Tumor, Angiosarcoma, Tissue Biopsy, and Liver Embolization.

 
 
 
 
Learn about our expert tiers
Learn More
Patrick Schoffski
Elite in Gastrointestinal Stromal Tumor
Elite in Gastrointestinal Stromal Tumor
Leuven, VLG, BE 

Patrick Schoffski practices in Leuven, Belgium. Mr. Schoffski is rated as an Elite expert by MediFind in the treatment of Gastrointestinal Stromal Tumor. His top areas of expertise are Gastrointestinal Stromal Tumor, Adult Soft Tissue Sarcoma, Liposarcoma, Tissue Biopsy, and Nephrectomy.

What are the latest Gastrointestinal Stromal Tumor Clinical Trials?
A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan (MK-6482, Formerly PT2977) Monotherapy in Participants With Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Advanced Solid Tumors With HIF-2α Related Genetic Alterations

Summary: This is a study to evaluate the efficacy and safety of belzutifan monotherapy in participants with advanced pheochromocytoma/paraganglioma (PPGL), pancreatic neuroendocrine tumor (pNET), von Hippel-Lindau (VHL) disease-associated tumors, advanced wt (wild-type) gastrointestinal stromal tumor (wt GIST), or advanced solid tumors with hypoxia inducible factor-2 alpha (HIF-2α) related genetic alterati...

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase 1a/1b Study of the Safety, Pharmacokinetics, and Antitumor Activity of the Oral Menin Inhibitor Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) After Imatinib Failure

Summary: In this clinical trial, the safety, tolerability, and preliminary antitumor activity of ziftomenib in combination with imatinib will be evaluated in adults with gastrointestinal stromal tumors (GIST) who have been treated previously with imatinib.

Who are the sources who wrote this article ?

Published Date: July 14, 2021
Published By: National Institutes of Health